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Objective: The objective of this study is to investigate whether chronic inflammatory 
demyelinating polyneuropathy (CIDP) and its subtypes differ in their type 1 T-helper (TH1) 
cell response against nodal/paranodal neurofascin (NF186, NF155) as well as myelin 
protein zero (P0 180–199) and myelin basic protein (MBP 82–100).
Methods: Interferon-gamma (IFN-γ) enzyme-linked immunospot assay was used to 
detect antigen-specific T cell responses in 48 patients suffering typical CIDP (n = 18), 
distal acquired demyelinating polyneuropathy (n = 8), multifocal acquired demyelinating 
sensory and motor polyneuropathy (MADSAM; n = 9), and sensory CIDP (n = 13) com-
pared to other non-immune polyneuropathy (ON; n = 19) and healthy controls (n = 9).
results: Compared to controls, MADSAM and sensory CIDP patients showed broadest 
IFN-γ T cell responses to all four antigens. Positive IFN-γ responses against two or more 
antigens were highly predictive for CIDP (positive predictive value =  0.95) and were 
found in 77% of CIDP patients. Patients with limited antigen-specific response were 
females, more severely affected with neuropathic pain and proximal paresis. The area 
under the receiver operating characteristics curve (AUC) of NF186 in MADSAM was 0.94 
[95% confidential interval (CI) 0.82–1.00] compared to ON. For sensory CIDP, AUC of P0 
180–199 was 0.94 (95% CI 0.86–1.00) and for MBP 82–100 0.95 (95% CI 0.88–1.00) 
compared to ON.
conclusion: Cell-mediated immune responses to (para)nodal and myelin-derived anti-
gens are common in CIDP. TH1 response against NF186 may be used as a biomarker 
for MADSAM and TH1 responses against P0 180–199 and MBP 82–100 as biomarkers 
for sensory CIDP. Larger multicenter studies study are warranted in order to establish 
these immunological markers as a diagnostic tools.
Keywords: chronic inflammatory demyelinating polyneuropathy, neurofascin, myelin basic protein, myelin protein 
zero, T cell response, chronic inflammatory demyelinating polyneuropathy subtypes
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inTrODUcTiOn
Chronic inflammatory demyelinating polyneuropathy (CIDP) 
is a rare autoimmune disorder of the peripheral nervous system 
and can be divided clinically into typical CIDP and atypical 
variants, such as distal acquired demyelinating polyneuropathy 
(DADS), multifocal acquired demyelinating sensory and motor 
polyneuropathy (MADSAM), and sensory CIDP (1, 2). Due to 
its heterogeneous manifestation, different autoimmune targets 
are likely to be relevant in CIDP (3). T cell responses have been 
shown to be involved in the immunopathogenesis of CIDP (4, 5). 
Previously, we and others detected autoreactive T cell responses 
against the compact myelin antigenic epitopes P2, PMP-22 as 
well as myelin protein zero 180–199 (P0 180–199), myelin basic 
protein 82–100 (MBP 82–100) measured by enzyme-linked 
immunospot (ELISPOT) assay (6–8). Additionally, we found dif-
ferences between typical and atypical CIDP in antigenic response 
against P0 180–199 and MBP 82–100 (8).
There is an emerging body of evidence that molecules of the 
nodal/paranodal complex may be essential targets for blocking 
propagation of nerve impulses along myelin fibers (9). Thus, 
autoantibodies against the paranodal protein neurofascin 155 
(NF155) have been identified in CIDP patients as well as patients 
suffering from combined central and peripheral demyelination 
(10, 11). Antibodies against the nodal NF186 have also been 
found in CIDP (12). The purpose of this study was to investigate 
whether CIDP patients show autoreactive T cell responses against 
NF155 and NF186 and secondly whether CIDP and its clinical 
variants differ in their T cell response against NF155, NF186 as 
well as against the myelin epitopes P0 180–199 and MBP 82–100.
MaTerials anD MeThODs
standard Protocol approvals, 
registrations, and Patient consent
The study was approved by the ethical committee of Charité 
University Medicine Berlin. All patients were recruited in the 
outpatient clinic of the Charité Department of Neurology. 
All patients gave their written informed consent for the study. 
Pseudonyms were used for the study.
Patients
For our study, 48 patients with typical CIDP (n = 18), DADS 
(n = 8), MADSAM (n = 9), and sensory CIDP (n = 13) were 
recruited. Diagnoses were made according to the criteria of 
the European Federation of Neurological Societies/Peripheral 
Nerve Society (EFNS/PNS) (13). We assessed the clinical condi-
tion of patients by Medical Research Council (MRC) (14), and 
the inflammatory neuropathy cause and treatment (INCAT) 
disability score (15). For classification, we used CIDP disease 
activity status (CDAS) (16), summarizing unstable active and 
improving status as unstable stage, stabile active status and 
remission status as stable stage. We used symptoms stated in 
case histories for analysis of clinical features. Patients had 
received no immunosuppressive drugs at the time of study 
entry or during the six previous months. Positive treatment 
response was defined as an improvement of two or more points 
on the MRC sum score in two different muscle groups, or an 
improvement of one point or more on the INCAT score, or 
an improvement of the walking distance of more than 50% 
compared to baseline results (6, 17). As controls, we included 
19 patients with other non-immune polyneuropathies (ONs) 
such as idiopathic axonal polyneuropathy (n = 13), metabolic 
or toxic polyneuropathy (n  =  1), hereditary polyneuropathy 
(n = 1) or diabetic polyneuropathy (n = 2), motoneuron disease 
(n = 1), ATTR amyloidosis-associated neuropathy (n = 1), and 
nine healthy controls (HCs). Clinical and experimental data 
of one patient have been submitted as a case report elsewhere 
(18). In addition, partial MBP and P0 response data from one 
MADSAM and one typical patient as well as six HCs have been 
published previously (8).
Blood samples
For ELISPOT, blood samples were collected using CPT tubes (BD 
Vacutainer, Becton, Dickinson and Company, Franklin Lakes, 
NJ, USA). In patients treated with intravenous immunoglobulins 
(IVIg), blood was obtained on the first day of IVIg-therapy before 
starting the infusion. Peripheral blood monocytes (PBMCs) were 
isolated within 3 h by density gradient centrifugation at 1,500 g 
for 20  min and diluted in CTL-Test-Medium (CTL-Europe, 
Bonn, Germany) at a concentration of 6 × 106 cells/mL.
elisPOT
For ELISPOT assay, we used our established protocol (6) based 
on the Elispot protocol established previously (19, 20). Briefly, 
96-well plates (Millipore, Billerica, MA, USA) were coated with 
an interferon-gamma (IFN-γ)-specific antibody (eBioscience, 
San Diego, CA, USA) at 4 µg/mL and left overnight in sterile PBS. 
After blocking with sterile PBS +  1% BSA (Sigma-Aldrich, St. 
Louis, MO, USA) for 60–120 min, fresh PBMCs were added in a 
number of 4 × 105 cells/well in presence of anti-CD28 antibody 
which enhances the costimulatory signal (21) (eBioscience) 
at 2  µg/mL. Peripheral myelin antigens MBP 82–100 and P0 
180–199 as well as NF155 and NF186 were added at 40 µg/mL. 
As a positive control, we used CEF at a concentration of 10 µg/
mL. CEF is a peptide pool containing 23 MHC class 1 restricted 
viral antigens (22). To detect spontaneous IFN-γ secretion, we 
used CTL-Test-Medium (CTL, Cleveland, OH, USA). Plates were 
incubated at 37°C and 5% CO2 for 24 h. For detection, we applied 
mouse anti-human IFN-γ biotin antibody (eBioscience) at a con-
centration of 2 µg/mL and conjugated at 1:1,000 to streptavidin-
horseradish-peroxidase (BioLegend, San Diego, CA, USA). 
Plates were developed with 3-amino-9-ethyl carbazole reagent 
Abbreviations: CIDP, chronic inflammatory demyelinating polyneuropathy; 
CDAS, CIDP disease activity status; DADS, distal acquired demyelinating 
polyneuropathy; ELISPOT, enzyme-linked immunospot; EFNS, European 
Federation of Neurological Societies; HC, healthy control; INCAT, inflammatory 
neuropathy cause and treatment; IFN-γ, interferon-gamma; IVIg, intravenous 
immunoglobulin; MADSAM, multifocal acquired demyelinating sensory and 
motor polyneuropathy; MBP/MBP 82–100, myelin basic protein 82–100; MRC, 
Medical Research Council; NF155, neurofascin 155; NF186, neurofascin 186; ON, 
other non-immune polyneuropathy; P0/P0 180–199, myelin protein zero 180–199; 
PBMCs, peripheral blood mononuclear cells.
FigUre 1 | Autoreactive T cell responses against neurofascin antigens are elevated in chronic inflammatory demyelinating polyneuropathy (CIDP) subtypes 
compared to controls. Frequency of peripheral antigen-specific T cell responses in patients with distal acquired demyelinating polyneuropathy (DADS) (n = 8), 
multifocal acquired demyelinating sensory and motor polyneuropathy (MADSAM) (n = 9), sensory CIDP (n = 13), typical CIDP (n = 18), other non-immune 
polyneuropathy (ON) (n = 19), and healthy control (HC) (n = 9) measured by enzyme-linked immunospot assay. Lines at median. Background corrected interferon-
gamma (IFN-γ) spot forming cells per 1 × 106 peripheral blood monocytes against neurofascin (NF) 155 (a) and NF186 (B) (***p < 0.001, **p < 0.01, *p < 0.05; 
Dunn’s multiple comparisons test). (a) Cutoff was defined at spot forming unit (SFU) ≥ 5 with sensitivity of 44.4% and specificity of 100% based on receiver 
operating characteristics (ROC) analysis comparing typical CIDP and ON [area under the ROC curve (AUC) = 0.83 with 95% confidence interval of 0.7–0.96]. (B) 
Cutoff was defined at SFU ≥ 5 with sensitivity of 66.7% and specificity of 100%, based on ROC analysis comparing MADSAM and ON (AUC = 0.94 with 95% 
confidence interval of 0.82–1).
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(Sigma Aldrich, St. Louis, MO, USA). The resulting spots were 
detected, counted and analyzed via Elispot Reader (Autoimmun 
Diagnostika GmbH, Strassberg, Germany) and appendant iSpot 
04 Software. Spot forming units (SFU) for each antigen triplicate 
were averaged and subtracted by average SFU of spontaneous 
IFN-γ secretion and then calculated for a cell quantity of 106 cells. 
Analyzing of the data was performed in a blinded fashion.
antigens
Recombinant NF155 and NF186 were kindly provided by E. 
Meinl (MD, LMU Munich, Germany) and were described earlier 
(10). P0 180–199 and MBP 82–100 were provided by R. Volkmer 
(SD, Charité Berlin, Germany) and were described earlier (8).
statistics
We compared clinical baseline measurements (age, time since 
diagnosis, MRC, INCAT) as well as antigen-specific IFN-γ 
responses using Kruskal–Wallis test followed by Dunn’s multiple 
comparison test or Mann–Whitney U-test, when suitable. Fisher’s 
exact test was used to compare frequencies of the non-metric clini-
cal parameters sex, response to IVIg-treatment, CDAS, tremor, 
sensory ataxia, neuropathic pain, asymmetric paresis, proximal 
paresis, drop foot, distal motoric latency, F-wave latencies, nerve 
conduction velocities, conduction block, and positive CSF. We 
calculated Spearman’s rho to analyze the relation of P0 to MBP. 
In order to evaluate the discrimination properties of the different 
antigen T cell responses for differentiating a specific type of CIPD 
from ON or other atypical CIPD variants, we calculated the area 
under the curve (AUC) and 95% confidential interval (CI) from 
receiver operating characteristics (ROC)-curve analyses. Good 
discriminative potential of an antigen response in a CIDP subtype 
compared to the control group was defined as an AUC > 7, which 
did not include 0.5 in 95% CI. To achieve higher discrimination 
properties, we also analyzed combinations of promising markers 
using multiple logistic regression with regard to the discrimina-
tion of specific disease types from ON. Statistical analyses were 
performed with GraphPad Prism version 6.0 (La Jolla, CA, USA). 
No adjustment for multiple testing was made. A p-value <0.05 
was considered significant.
resUlTs
identification of neurofascin- and Myelin-
Derived antigens as T cell Targets in ciDP
The NF155-specific IFN-γ response was higher in typical CIDP 
and MADSAM than in HC and ON (Figure  1A). Similarly, 
the IFN-γ response against NF186 was significantly increased 
in MADSAM and to a lesser extent in typical CIDP compared 
to HC and ON (Figure  1B). By using post  hoc defined cutoff 
values (Figure 1), 9 out of 18 (50%) typical CIDP as well as 4/9 
(44%) MADSAM patients responded to NF155. For NF186, 
5/18 (28%) typical CIDP and 6/9 (67%) MADSAM patients 
exhibited positive IFN-γ responses. In contrast, DADS and 
sensory CIDP showed lower IFN-γ responses to NF155 and 
NF186. Importantly, ON and HC showed no NF-specific IFN-γ 
response at all. Type 1 T-helper (TH1) responses against CEF 
positive controls showed no differences between any of the 
groups (data not shown).
FigUre 2 | Compact myelin-specific T cell responses are elevated in chronic inflammatory demyelinating polyneuropathy (CIDP) subtypes compared to controls. 
Frequency of peripheral antigen-specific T cell responses in patients with demyelinating polyneuropathy (DADS) (n = 8), multifocal acquired demyelinating sensory 
and motor polyneuropathy (MADSAM) (n = 9), sensory CIDP (n = 13), typical CIDP (n = 16), other non-immune polyneuropathy (ON) (n = 19), and healthy control 
(HC) (n = 9) measured by enzyme-linked immunospot assay. Lines at median. Background corrected interferon-gamma (IFN-γ) spot forming cells per 1 × 106 
peripheral blood monocytes against myelin protein zero (P0) 180–199 (a) and myelin basic protein (MBP) 82–100 (B) (***p < 0.001, **p < 0.01, *p < 0.05; Dunn’s 
multiple comparisons test). (a) Cutoff was defined at spot forming unit (SFU) ≥ 5 with sensitivity of 92.3% and specificity of 84.2%, based on receiver operating 
characteristics (ROC) analysis comparing sensory CIDP and ON [area under the ROC curve (AUC) = 0.94 with 95% confidence interval of 0.86–1]. (B) Cutoff was 
defined at SFU ≥ 5 with sensitivity of 92.3% and specificity of 89.5% based on ROC analysis comparing sensory CIDP and ON (AUC = 0.95 with 95% confidence 
interval of 0.88–1). (c) IFN-γ reaction to MBP in correlation to P0 as measured by Spearman correlation with r = 0.82 (p < 0.001).
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Serum samples from patients with immune-polyneuropathy 
and from controls with other polyneuropathies were analyzed for 
antibodies to NF155 and NF186 by ELISA. However, none of our 
samples showed antibody reactivity specific to NF155 or NF186 
(data not shown).
Sensory CIDP and typical CIDP patients showed significantly 
elevated P0 180–199-specific IFN-γ secretion compared to both 
control groups, whereas DADS patients differed significantly 
only from HC (Figure 2A). IFN-γ response to MBP 82–100 was 
elevated in all CIDP subtypes (Figure 2B). For P0 180–199, we 
found a positive response in 11/16 (69%) typical CIDP, in 12/13 
(92%) sensory CIDP, in 5/9 (56%) MADSAM and in 4/8 (50%) 
DADS patients when we used post  hoc defined cutoffs (legend 
Figure 2). For MBP, a positive response was detected in 10/16 
(63%) typical CIDP patients, in 12/13 (92%) sensory CIDP, in 
6/9 (67%) MADSAM and in 4/8 (50%) DADS patients. For ON, 
we found P0-specific responses in 3/19 (16%) and MBP-specific 
responses in 2/19 (11%), whereas investigation of HC samples 
revealed no antigen-specific T  cell responses. Interestingly, 
there was a positive correlation between P0 180–199- and MBP 
82–100-specific IFN-γ responses (r = 0.82; p < 0.001; Spearman 
r; Figure 2C).
In ROC analysis, the anti-NF155 response exhibited good 
discrimination properties when we compared typical CIDP or 
MADSAM to ON (Table  1A) but not to other CIDP subtypes 
(Table  1B). The AUC of NF186 was highest in MADSAM 
compared to ON (Table  1A) but also to other CIDP subtypes 
(Table  1B). The P0 180–199 response demonstrated good 
discrimination properties against ON in all but the MADSAM 
group, and MBP 82–100 had good discriminative potential 
between each CIDP subtype and ON (Table  1A). AUCs of P0 
and MBP were highest in sensory CIDP compared to ON and by 
trend to other CIDP subtypes (Table 1). Combinations of all four 
markers indicated an advantage over using only the best single 
biomarker, but improvement was not significant (Table 1A).
antigen-specific iFn-γ response as 
supportive Diagnostic criteria for ciDP
We used cutoff values (Figure  11) to define positive responses 
to tested antigens. In contrast to ON, positive IFN-γ responses 
against two or more antigens proved highly predictive for any 
subtype of CIDP (positive predictive value =  0.95) and were 
found in 77% of CIDP patients (Figure  3). Negative IFN-γ 
responses to three or four antigens were observed in 23% CIDP 
patients (Figure 3; negative predictive value = 0.61). In contrast, 
only two patients (10.5%) of ON showed responses against at least 
two antigens; 89.5% did not. These two responding patients had 
been diagnosed with diabetic polyneuropathy based on clinical 
manifestation and nerve conduction studies. Regarding the dis-
tribution for each CIDP subtype, we found that MADSAM and 
sensory CIDP most often displayed widespread antigen-specific 
response in contrast to DADS, where the majority responded 
only to one or two antigens (Figure 3).
clinical characteristics of Patients 
stratified by antigen-specific T cell 
responses
Asymmetric paresis was seen in the NF186 responsive group. The 
MBP responsive group was male and showed a shorter disease 
duration compared to the MBP-unresponsive group. Similarly, 
patients responsive to P0 were male and younger than the P0 




n total nF155 nF186 P0 180–199a MBP 82–100a p-Valueb aUc (95% ci) for 
combination of all 4 
markers p-Valuec
a. aUc (95% ci) of specific subtype versus On
Typical CID0 18 37 0.83 (0.70––0.96) 0.75 (0.62–0.89) 0.82 (0.68–0.96) 0.77 (0.61–0.93) 0.664 0.86 (0.73–1.00) (p = 0.362)
DADS 8 27 0.65 (0.42–0.88) 0.72 (0.52–0.93) 0.81 (0.64–0.99) 0.88 (0.76–1.00) 0.043 0.95 (0.86–1.00) (p = 0.147)
MADSAM 9 28 0.85 (0.67–1.00) 0.94 (0.82–1.00) 0.69 (0.44–0.94) 0.92 (0.83–1.00) 0.094 1.00 (1.00–1.00) (p = 0.318)
Sensory CIDP 13 32 0.67 (0.50–0.86) 0.74 (0.59–0.90) 0.94 (0.86–1.00) 0.95 (0.88–1.00) 0.011 0.99 (0.97–1.00) (p = 0.183)
B. aUc (95% ci) of specific subtype versus all other subtypes
Typical CIDP 18 48 0.62 (0.45–0.78) 0.53 (0.35–0.7) 0.51 (0.33–0.7) 0.57 (0.37–0.76) 0.602
DADS 8 48 0.63 (0.43–0.84) 0.64 (0.44–0.83) 0.54 (0.31–0.77) 0.55 (0.32–0.79) 0.907
MADSAM 9 48 0.57 (0.38–0.77) 0.76 (0.59–0.93) 0.68 (0.49–0.87) 0.52 (0.34–0.7)  <0.001
Sensory CIDP 13 48 0.6 (0.42–0.79) 0.58 (0.4–0.75) 0.65 (0.49–0.81) 0.63 (0.47–0.8) 0.504
Results of ROC analysis of each antigen IFN-γ response to study discriminative potential of antigenic T cell response between CIDP subtypes and ON (A) or compared to other 
subtypes (B).
aTwo values are missing in group of typical CIDP.
bp-Value of differences between markers.
cp-Value of combination of all four vs. best single marker.
CIDP, chronic inflammatory demyelinating polyneuropathy; DADS, distal acquired demyelinating polyneuropathy; MADSAM, multifocal acquired demyelinating sensory and motor 
polyneuropathy; MBP 82–100, myelin basic protein 82–100; NF155, neurofascin 155; NF186, neurofascin 186; ON, other non-immune polyneuropathy; P0 180–199, myelin protein 
zero 180–199.
FigUre 3 | Diversity of antigenic response in chronic inflammatory demyelinating polyneuropathy (CIDP) and subtypes. The percentage of reactivity against four, 
three, two, one, or none of the tested antigens [neurofascin (NF) 155, NF186, P0 180–199, and MBP 82–100] is shown in other non-immune polyneuropathy (ON), 
demyelinating polyneuropathy (DADS), multifocal acquired demyelinating sensory and motor polyneuropathy (MADSAM), sensory, typical CIDP as well as all CIDP 
patients. The immune response against at least two antigens was most frequently in sensory CIDP (92.3%), MADSAM (77.7%), and typical CIDP (72.2%) compared 
to DADS (62.5%) and ON (10.5%).
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negative group. Looking at demyelinating parameters, we found 
by trend an association between the NF186 response and conduc-
tion blocks (p = 0.06; Fisher’s exact test). Clinical disease activity 
status, however, improvement upon IVIg-treatment, or clinical 
features such as tremor and ataxia were independent of T  cell 
reaction specific to NF155, NF186, P0 180–199, or MBP 82–100 
(Table  2). Limited antigen-specific T  cell responses (response 
against <2 antigens) were seen in patients who were female and 
older than patients who showed a positive response against ≥2 
antigens. Patients with limited antigen-specific response showed 
a lower MRC and increased INCAT score as well as more neuro-
pathic pain and proximal paresis. F-wave latencies were less likely 
to be prolonged (Table 2).
DiscUssiOn
In the present study, we demonstrated specific IFN-γ T  cell 
responses against the paranodal/nodal antigens NF155 and 
NF186 as well as against myelin-derived antigens MBP 82–100 
and P0 180–199 in CIDP compared to ON. Positive IFN-γ 
responses against two or more antigens were highly predictive 
for any subtype of CIDP, with MADSAM and sensory CIDP 
showing the broadest immune response to the four tested anti-
gens. ROC analysis indicated highest discriminative potential of 
NF186-specific T  cell responses in MADSAM and the highest 
discriminative potential of P0 180–199 and MBP 82–100-spe-
cific response in sensory CIDP, suggesting the presence of cell-
mediated immune responses against these antigens as a suitable 
biomarker for CIDP diagnosis.
The autoreactive T cell responses against NF155 and NF186 
that we demonstrated here for typical CIDP and MADSAM might 
be of particular relevance. Recently, IgG4 antibodies to NF155 
have been found in a clinically distinct subgroup of CIDP that 
show a younger age at onset, tremor, ataxia, CNS demyelination 
and a poor response to IVIg treatment which was not compatible 
with established EFNS classification criteria (11, 23). Based on 
TaBle 2 | Clinical characteristics of ELISPOT antigen-responsive patients and patients with limited antigen-specific response.
nF155 pos. nF186 pos. P0 180–199 pos. MBP 82–100 pos. limited response (<2 antigen pos.)
n of patient (%) 19/48 (40) 14/48 (29) 32/48 (67) 32/48 (67) 11/48 (23)
Sex, male (%) 14 (74) 11 (79) 26 (81)a 26 (81)a 4 (36)b
Age, mean (range) 58 (27–80) 61 (53–77) 60 (27–82)a 60 (27–82) 73 (63–77)b
Time since diagnosis, median (range) 4 (0–10) 3 (0–10) 3 (0–17) 2 (0–17)a 5 (1–23)
Good response to IVIg-therapy, n (%) 16/18 (89) 11/14 (79) 21/29 (72) 23/30 (77) 9/10 (90)
Unstable disease, n (%) 8 (42) 8 (57) 16 (50) 17 (53) 6 (55)
MRC, mean (range) 74 (63–80) 74 (66–78) 73 (45–80)a 73 (45–80) 72 (62–76)b
INCAT, median (range) 3 (1–4) 3 (1–6) 3 (1–7) 3 (1–7) 4 (2–6)b
Tremor, n (%) 8 (42) 6 (43) 12 (38) 13 (41) 8 (73)
Sensory ataxia, n (%) 14 (74) 10 (71) 22 (69) 20 (63) 9 (82)
Neuropathic pain, n (%) 7 (37) 6 (43) 13 (41) 13 (41) 10 (91)c
Asymmetric paresis, n (%) 9 (47) 10 (71)a 13 (41) 14 (44) 3 (27)
Proximal paresis, n (%) 10 (52) 10 (71) 12 (38)a 13 (41) 9 (82)b
Drop foot, n (%) 13 (68) 12 (86) 18 (56) 18 (56) 10 (91)
Distal motoric latency, n (%) 8 (42) 5 (36) 10 (31) 9 (28) 5 (10)
F-wave latencies, n (%) 15 (79) 12 (86) 23 (72) 22 (69) 4 (8)b
Nerve conduction velocities, n (%) 15 (79) 8 (57) 20 (63) 20 (63) 7 (15)
Conduction block, n (%) 4 (21) 6 (43) 7 (22) 9 (28) 2 (4)
Positive CSF, n (%) 13 (68) 10 (71) 16 (50)a 16 (50)a 8 (17)
Positive electroneurographic parameters (prolonged distal motor latency, F-wave latency, nerve conduction velocity, conduction block) were defined according electrodiagnostic 
criteria of EFNS (13).
ap-Value for antigen positive patients in comparison to negative group: p < 0.05.
bp-Value for group of patients with negative reaction to three or more antigens in comparison to group with two or more positive reaction: p < 0.05.
cp-Value for group of patients with negative reaction to three or more antigens in comparison to group with two or more positive reaction: p < 0.001.
INCAT, inflammatory neuropathy cause and treatment; IVIg, intravenous immunoglobulin; MBP 82–100, myelin basic protein 82–100; MRC, Medical Research Council; NF155, 
neurofascin 155; NF186, neurofascin 186; P0 180–199, myelin protein zero 180–199.
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the fact, that NF155-specific antibodies have been found in this 
clinically distinctive subgroup, we also correlated antigen-specific 
IFN-γ response with a number of clinical features (Table 2). We 
did not find any association between ataxia, tremor, pain, or 
type of paresis. In contrast to recent NF155 antibody studies 
(11), however, patients showing IFN-γ T cell responses against 
NF155 responded well to immunomodulatory treatment, which 
may suggest a more active T cell driven autoimmune process. In 
the present study, we found that positive T cell responses against 
NF155 and NF186 were more frequent than has been reported 
up to now in published antibody findings (10, 11, 23). This sup-
ports the hypothesis of an underlying T cell-mediated immune 
response (5, 6). Our results of NF-specific T cell reactivity further 
support the importance of the Ranvier node as an immunologi-
cal target in CIDP. However, evidence is still lacking whether the 
detected antigen-specific T cell response may contribute to the 
disease. On the other hand, T cell response may just have evolved 
by tissue damage and not be pathogenic. Based on our control 
data of patients with non-immune neuropathy showing no or 
very low T  cell reactivity a secondary immune response does 
not seem to play an important role. The elevated IFN-γ response 
against NF186 in MADSAM was clearly distinct from ON and 
other CIDP subtypes, which points to NF186 as a promising 
diagnostic marker to be validated in a larger multicentric study.
In the present study, we detected IFN-γ responses against P0 
and MBP in 67% of our CIDP cohort. P0 is one of the major 
peripheral myelin proteins that functions as autoantigen in mod-
els of autoimmune peripheral neuropathy (24, 25). There is still 
little evidence about the role of MBP 82–100 in the pathogenesis 
of CIDP even though MBP has been detected as part of the myelin 
sheath of peripheral nerves (26). Here, we found in CIDP elevated 
IFN-γ responses against both P0 and MBP that show highest 
discriminating properties in sensory CIDP compared to ON and 
by trend to other subtypes. Sensory CIDP is often difficult to dif-
ferentiate from non-immune polyneuropathy, since it often does 
not correspond with the current EFNS/PNS diagnostic criteria 
(13, 27, 28). P0 180–199 and MBP 82–100-specific responses may 
therefore be suitable candidates as diagnostic markers to support 
the diagnosis of sensory CIDP. Early diagnosis of CIDP and 
treatment initiation is essential in order to prevent irreversible 
axonal damage and thus disability. On the other hand, there is 
increasing evidence that many patients are misdiagnosed with 
CIDP. Recently, Allen et al. showed in a retrospective analysis of 
58 patients that about 47% of all cases had been misdiagnosed 
with CIDP and subsequently treated for long periods without 
clear evidence for efficacy of treatment (27). A diagnostic marker 
could help to prevent misdiagnosis and reduce side effects and 
costs of unnecessary treatment. It would be therefore of high rel-
evance to validate our findings in larger multicentric studies. Even 
though this study is comparatively large, with a total number of 48 
patients, it is still too small to firmly identify T cell epitopes and 
correlate them with clinical features or a specific CIDP subtype. 
Another limitation may be the fact that the patients included 
were not treatment-naive and had a rather long disease duration. 
This may have affected our results and thus limit the predictive 
evidence. Despite the fact that CIDP single subtype divisions 
are small we still found significant higher antigen-specific T cell 
responses compared to controls whereas no difference could be 
found for the control peptide pool (CEF). Thus, our prospectively 
generated explorative data support a strong hypothesis. However, 
due to the small numbers of CIDP subtypes the present work 
represents a basis for validation in a greater multicenter study 
7Diederich et al. Neurofascin T Cell Response in CIDP
Frontiers in Neurology | www.frontiersin.org March 2018 | Volume 9 | Article 171
In addition, including other demyelinating diseases such as 
Guillain-Barré-Syndrom, Multifocal Motoric Neuropathy of 
hereditary Charcot-Marie-Tooth1 neuropathy as controls would 
be helpful for understanding pathomechanism as well as for 
developing T  cell-specific responses as a biomarker of CIDP. 
For that, the Elispot assay provides robust, highly reproducible 
data. The Elispot technique can be easily used with frozen and 
subsequently thawed PBMCs. ELISPOT appears to be one of the 
fast growing applications in biomedical research such as in vac-
cine development (29), HIV research (30), and cancer and allergy 
research (31), most of them in multicenter trials. Furthermore, 
comparative B and T cell ELISPOT assays are useful in the process 
control of kidney transplant recipients (32). The great advantage 
of ELISPOT assay over flow cytometry is its unsurpassed sen-
sitivity in detecting low frequency antigen-specific T  cells that 
secrete effector molecules. A simultaneously performed T and 
B cell ELISPOT assay in patients with CIDP could allow a direct 
comparison of memory T and B cell response in the peripheral 
blood. Since PBMCs can be efficiently frozen without loss of 
function when tested in ELISPOT assay, it can be easily used to 
investigate suitable progression or treatment efficacy parameters.
In our cohort, eleven CIDP patients showed only a limited 
antigen-specific response. Looking at their clinical characteristics, 
we found these patients were older, had a longer disease duration, 
a lower MRC, and increased INCAT score with manifest long-
term damages such as severe paresis and pain syndromes. Thus, 
the lack in autoimmune responses in this non-responder group 
could be attributable to a somewhat “burnt-out” disease status. 
We observed asymmetric paresis in the NF186 responsive group, 
which is compatible with the clinical definition of MADSAM 
patients. Patients responding to MBP and P0 were male and 
younger than those in the non-responsive group. This concurs 
with a recent clinical description of sensory CIDP (28). In con-
trast, there were two patients in the ON group who responded to 
two antigens. These patients had been diagnosed with diabetic 
polyneuropathy based on clinical manifestation and nerve con-
duction studies. However, the antigenic response in these patients 
may suggest an underlying immune-mediated mechanism as is 
being discussed with increasing frequency regarding some forms 
of diabetic neuropathy (33, 34).
In summary, we provide evidence for underlying auto-
reactive T  cell immune responses against neurofascin as well 
as compact myelin epitopes in CIDP and variants. P0 180–199 
and MBP 82–100 IFN-γ responses were associated with sensory 
CIDP, whereas NF186-specific IFN-γ response was associated 
with MADSAM. Further multicentric studies including other 
inflammatory neuropathies are required to validate these promis-
ing biomarkers with reliable cut offs as useful diagnostic tools for 
CIDP, its subtypes, and for treatment guidance.
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